What's in Takeda Pharmaceutical Company Limited's pipeline?

Takeda Pharmaceutical Company Limited has 223 drugs in our index: 58 marketed, 0 filed, 58 in Phase 3, 46 in Phase 2, 61 in Phase 1.

Which companies overlap with Takeda Pharmaceutical Company Limited's portfolio?

Top competitors by shared drug class: Pfizer, Sanofi, GlaxoSmithKline, Novartis, Bayer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/takeda.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Takeda Pharmaceutical Company Limited — Portfolio Competitive Intelligence Brief

Takeda Pharmaceutical Company Limited (TAK) pipeline: 58 marketed, 0 filed, 58 Phase 3, 46 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

TAK (NYSE) 58 marketed 0 filed 58 Phase 3 46 Phase 2 61 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Livtencity	MARIBAVIR	marketed	Cytomegalovirus pUL97 Kinase Inhibitor [EPC]		Oncology	2021-01-01
Exkivity	MOBOCERTINIB	marketed	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-4	Oncology	2021-01-01
Alunbrig	brigatinib	marketed	Kinase Inhibitor [EPC]	ALK tyrosine kinase receptor	Oncology	2017-01-01
Ninlaro	IXAZOMIB	marketed	Proteasome Inhibitor	Proteasome subunit beta type-5	Oncology	2015-01-01
Nesina	ALOGLIPTIN	marketed	Dipeptidyl Peptidase 4 Inhibitor	Dipeptidyl peptidase 4	Metabolic	2013-01-01
Trintellix	vortioxetine	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	Neuroscience	2013-01-01
Gattex Kit	TEDUGLUTIDE	marketed	GLP-2 Analog [EPC]	Glucagon-like peptide 2 receptor	Metabolic	2012-01-01
Firazyr	ICATIBANT	marketed	Bradykinin B2 Receptor Antagonist	B2 bradykinin receptor	Neuroscience	2011-01-01
Uloric	FEBUXOSTAT	marketed	Xanthine Oxidase Inhibitor [EPC]	Xanthine dehydrogenase/oxidase	Immunology	2009-01-01
Mepact	MIFAMURTIDE	marketed	mifamurtide	Nucleotide-binding oligomerization domain-containing protein 2	Oncology	2009-01-01
Dexilant	DEXLANSOPRAZOLE	marketed	Proton Pump Inhibitor [EPC]	(H+, K+)-ATPase	Pain	2009-01-01
Vyvanse	LISDEXAMFETAMINE	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	Metabolic	2007-01-01

Therapeutic area mix

Diabetes · 22
Cardiovascular · 17
Oncology · 16
Metabolic · 7
Gastroenterology · 6
Immunology · 6
Neuroscience · 5
Other · 4
Immunology / Gastroenterology · 2
Immunology / Infectious Disease · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2028-01-18 — Versed · 9687495 · Formulation · US
2028-01-18 — Versed · 9289432 · Formulation · US
2028-01-18 — Versed · 8217033 · Formulation · US
2028-01-18 — Versed · 8809322 · Formulation · US
2028-02-01 — Omnaris · 8371292 · US
2038-06-20 — Versed · 10966990 · Formulation · US

Competitive overlap (companies sharing drug classes)

Pfizer · 11 shared drug classes
Sanofi · 9 shared drug classes
GlaxoSmithKline · 9 shared drug classes
Novartis · 8 shared drug classes
Bayer · 6 shared drug classes
Merck Sharp & Dohme LLC · 6 shared drug classes
AstraZeneca · 5 shared drug classes
Hanmi Pharmaceutical Company Limited · 4 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Takeda Pharmaceutical Company Limited:

Cite this brief

Drug Landscape (2026). Takeda Pharmaceutical Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/takeda. Accessed 2026-05-13.